Roche - Mission: Possible – novel anti-CD20 promise for lupus nephritis?


Industry room 2
English
Satellite Symposia
04 June 2021 08:15 - 09:45

Overall objectives:

  • Present current perspectives on the pathogenesis of lupus nephritis (LN)
  • Review the unmet medical need in LN and the limitations of current standard of care
  • Explain the importance of targeting B cells and the scientific rationale for anti-CD20 monoclonal antibody approaches in LN
  • Consider future directions for using anti-CD20 monoclonal antibodies in LN and related autoimmune conditions

Two lectures plus a panel discussion between the faculty members will review current evidence and share exert perspectives on key topics in LN.

 

Deciphering the complexities of LN

This presentation will focus on the autoimmune basis of disease and pathogenesis of LN, explore the burden of disease and summarise current approaches to diagnosis and treatment.

 

How anti-CD20 therapies are advancing the treatment of LN

This presentation will review the benefits of targeting CD20 for B-cell depletion and review the evidence from trials of anti-CD20 approaches to explain the scientific rationale driving this therapeutic approach in LN

 

Panel discussion: Optimising anti-CD20 therapy for LN

In this panel discussion the faculty will explore the design of the obinutuzumab Phase 3 trial in LN and will discuss the potential of anti-CD20 therapy in other areas of LN and for extrarenal disease


Presentations

Title Time Calendar .ics
Welcome and introduction
04 June 2021 08:15 - 08:20 .ics
Deciphering the complexities of LN
04 June 2021 08:20 - 08:35 .ics
How anti-CD20 therapies are advancing the treatment of LN
04 June 2021 08:35 - 08:50 .ics
Panel discussion: Optimising anti-CD20 therapy for LN
04 June 2021 08:50 - 09:10 .ics
Question and answer session/general discussion
04 June 2021 09:10 - 09:15 .ics